依托泊苷胶囊联合安罗替尼一线维持治疗老年小细胞肺癌的临床观察

Clinical Observation of Etoposide Capsule Combined with Anlotinib as First-Line Maintenance Therapy for Elderly Patients with Small Cell Lung Cancer

目的探讨依托泊苷胶囊联合安罗替尼一线维持治疗老年小细胞肺癌的疗效和安全性。方法回顾性分析2017年10月—2019年12月我院收治的一线化疗后给予依托泊苷胶囊联合安罗替尼维持治疗的15例老年小细胞肺癌患者的临床资料。患者治疗方案为依托泊苷胶囊50 mg口服,每日1次,d1-d21,28 d为1个周期;安罗替尼10 mg口服,每日1次,d1-d14,21 d为1个周期。每2个周期评价疗效及随访患者生存状况,每周期评价不良反应,直至出现不可耐受的不良反应或疾病进展。结果15例患者均可评价疗效。其中部分缓解(PR)2例、病情稳定(SD)9例、疾病进展(PD)4例,客观缓解率(ORR)13.3%,疾病控制率(DCR)73.3%,中位无进展生存期(PFS)5.1个月,中位总生存期(OS)11.8个月。主要不良反应为血液学毒性、肝功能异常、恶心呕吐、腹泻、高血压、低钠血症,无治疗相关性死亡。结论依托泊苷胶囊联合安罗替尼一线维持治疗老年小细胞肺癌疗效较好,不良反应可耐受,安全性较好。

Objective To investigate the efficacy and safety of etoposide capsule combined with anlotinib as first-line maintenance therapy for elderly patients with small cell lung cancer.Methods A retrospective study was performed on 15 elderly patients with small cell lung cancer who received etoposide capsule combined with anlotinib as first-line maintenance therapy between October 2017 and December 2019.Patients got etoposide capsule 50 mg orally once a day,from the first day to the twenty-first day,twenty-eight days as a cycle.Anlotinib was given orally with 10 mg once a day,from the first day to the fourteenth day,twenty-one days as a cycle.The response was evaluated every two cycles.The adverse reactions were evaluated every cycle until disease progression or intolerable adverse reaction.Results All the patients completed the response evaluation.Two cases achieved partial response.Nine cases had disease stable,and four cases had disease progressed.The objective response rate(ORR)was 13.3%,and the disease control rate(DCR)was 73.3%.The median progression-free survival(PFS)was 5.1 months,and the median overall survival(OS)was 11.8 months.The major adverse reactions included hematology toxicity,abnormal liver function,nausea and vomiting,diarrhea,hypertension,hyponatremia.There was no treatment-related death.Conclusion Etoposide capsule combined with anlotinib as first-line maintenance therapy showed good effect and tolerance for elderly patients with small cell lung cancer.